BR112023025616A2 - Codificação de ácido nucleico para proteína de fusão klk2-gpi, células recombinantes e usos das mesmas - Google Patents
Codificação de ácido nucleico para proteína de fusão klk2-gpi, células recombinantes e usos das mesmasInfo
- Publication number
- BR112023025616A2 BR112023025616A2 BR112023025616A BR112023025616A BR112023025616A2 BR 112023025616 A2 BR112023025616 A2 BR 112023025616A2 BR 112023025616 A BR112023025616 A BR 112023025616A BR 112023025616 A BR112023025616 A BR 112023025616A BR 112023025616 A2 BR112023025616 A2 BR 112023025616A2
- Authority
- BR
- Brazil
- Prior art keywords
- klk2
- fusion protein
- nucleic acid
- gpi
- recombinant cells
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21035—Tissue kallikrein (3.4.21.35)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
- C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
- C07K2319/912—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation containing a GPI (phosphatidyl-inositol glycane) anchor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163209019P | 2021-06-10 | 2021-06-10 | |
| PCT/IB2022/055355 WO2022259190A1 (en) | 2021-06-10 | 2022-06-08 | Nucleic acid coding for klk2-gpi fusion protein, recombinant cells, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023025616A2 true BR112023025616A2 (pt) | 2024-02-27 |
Family
ID=82358484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023025616A BR112023025616A2 (pt) | 2021-06-10 | 2022-06-08 | Codificação de ácido nucleico para proteína de fusão klk2-gpi, células recombinantes e usos das mesmas |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220403397A1 (enExample) |
| EP (1) | EP4352217A1 (enExample) |
| JP (1) | JP2024520790A (enExample) |
| KR (1) | KR20240021211A (enExample) |
| CN (1) | CN117480253A (enExample) |
| AU (1) | AU2022291273A1 (enExample) |
| BR (1) | BR112023025616A2 (enExample) |
| CA (1) | CA3222756A1 (enExample) |
| IL (1) | IL309179A (enExample) |
| MX (1) | MX2023014793A (enExample) |
| WO (1) | WO2022259190A1 (enExample) |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| GB8901778D0 (en) | 1989-01-27 | 1989-03-15 | Univ Court Of The University O | Manipulatory technique |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| DE69233013T2 (de) | 1991-08-20 | 2004-03-04 | The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| US5602299A (en) | 1992-09-23 | 1997-02-11 | Mount Sinai School Of Medicine Of The City University Of New York | Transgenic animal models for neurodegenerative disease |
| EP1024198A3 (en) | 1992-12-03 | 2002-05-29 | Genzyme Corporation | Pseudo-adenoviral vectors for the gene therapy of haemophiliae |
| EP0705344B8 (en) | 1993-06-24 | 2006-05-10 | Advec Inc. | Adenovirus vectors for gene therapy |
| US5516639A (en) * | 1993-07-22 | 1996-05-14 | Mayo Foundation For Medical Education And Research | Antibodies specific for human prostate glandular kallkrein |
| AU687117B2 (en) | 1993-10-25 | 1998-02-19 | Canji, Inc. | Recombinant adenoviral vector and methods of use |
| JPH07132033A (ja) | 1993-11-12 | 1995-05-23 | Hoechst Japan Ltd | アルツハイマー病モデルトランスジェニック動物 |
| US6113917A (en) * | 1995-04-25 | 2000-09-05 | Rmf Dictagene S.A. | Modified polypeptides for enhanced immunogenicity |
| US6066778A (en) | 1996-11-06 | 2000-05-23 | The Regents Of The University Of Michigan | Transgenic mice expressing APC resistant factor V |
| DK1716233T3 (da) * | 2004-01-30 | 2009-10-26 | Maxygen Holdings Ltd | Reguleret stopkodongennemlæsning |
| AU2005295421A1 (en) * | 2004-10-18 | 2006-04-27 | Zymogenetics, Inc. | Soluble Zcytor21, anti-Zcytor21 antibodies and binding partners and methods of using in inflammation |
| EP2315846A4 (en) * | 2008-08-05 | 2011-11-30 | Univ Rochester | PSA AND KLK2 AS THERAPEUTIC TARGET MOLECULES AND PSA AND KLK2-INHIBITABLE MOLECULES |
| WO2012068317A2 (en) * | 2010-11-16 | 2012-05-24 | Excelimmune, Inc. | Methods for producing recombinant proteins |
| JP7235436B2 (ja) * | 2014-11-10 | 2023-03-08 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 細胞の表面上にポリペプチドを発現させるための組成物および方法 |
| AU2020322221A1 (en) * | 2019-07-26 | 2022-03-24 | Janssen Biotech, Inc. | Anti-hK2 chimeric antigen receptor (CAR) |
-
2022
- 2022-06-08 KR KR1020247000497A patent/KR20240021211A/ko active Pending
- 2022-06-08 CA CA3222756A patent/CA3222756A1/en active Pending
- 2022-06-08 AU AU2022291273A patent/AU2022291273A1/en active Pending
- 2022-06-08 WO PCT/IB2022/055355 patent/WO2022259190A1/en not_active Ceased
- 2022-06-08 JP JP2023575724A patent/JP2024520790A/ja active Pending
- 2022-06-08 MX MX2023014793A patent/MX2023014793A/es unknown
- 2022-06-08 BR BR112023025616A patent/BR112023025616A2/pt not_active Application Discontinuation
- 2022-06-08 EP EP22735984.1A patent/EP4352217A1/en active Pending
- 2022-06-08 IL IL309179A patent/IL309179A/en unknown
- 2022-06-08 CN CN202280041004.7A patent/CN117480253A/zh active Pending
- 2022-06-08 US US17/835,671 patent/US20220403397A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4352217A1 (en) | 2024-04-17 |
| CN117480253A (zh) | 2024-01-30 |
| MX2023014793A (es) | 2024-03-25 |
| US20220403397A1 (en) | 2022-12-22 |
| AU2022291273A1 (en) | 2024-01-25 |
| KR20240021211A (ko) | 2024-02-16 |
| WO2022259190A1 (en) | 2022-12-15 |
| CA3222756A1 (en) | 2022-12-15 |
| JP2024520790A (ja) | 2024-05-24 |
| IL309179A (en) | 2024-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022015628A2 (pt) | Vacina de sars-cov-2 | |
| BR112023005674A2 (pt) | Construtos anti-cd93 e usos dos mesmos | |
| BR112022021459A2 (pt) | Nucleases guiadas por rna, fragmentos ativos e variantes das mesmas e métodos de uso | |
| AR108442A1 (es) | Proteínas de fusión gdf15 y usos de estas | |
| WO2021198706A3 (en) | Coronavirus vaccines | |
| AR038568A1 (es) | Anticuerpos anti-a beta y su uso | |
| NO20020861L (no) | Nye B7-4-molekyler og anvendelser derav | |
| BR112022016789A2 (pt) | Formulações e usos das mesmas | |
| BR9914777A (pt) | Moléculas isoladas de ácido nucléico que codificam os fatores induzìveis por células t (tifs), as proteìnas codificadas e os usos das mesmas | |
| BR112022024629A2 (pt) | Construtos anti-cd93 e seus usos | |
| BR112021017464A2 (pt) | Receptores de células t e métodos de uso dos mesmos | |
| BR112021017486A2 (pt) | Receptores de células t e métodos de uso dos mesmos | |
| BR112022008201A2 (pt) | Degradação de proteínas de superfície usando agente de ligação biespecífico | |
| EA202190267A1 (ru) | Способы и композиции с использованием рекомбинантных дендритных клеток для терапии рака | |
| BR112021017479A2 (pt) | Receptores de células t e métodos de uso dos mesmos | |
| BR112021017491A2 (pt) | Receptores de células t e métodos de uso dos mesmos | |
| BR112021017505A2 (pt) | Receptores de células t e métodos de uso dos mesmos | |
| BR112021017467A2 (pt) | Receptores de células t e métodos de uso dos mesmos | |
| MX2022013416A (es) | Polipeptidos de fusion para la produccion de peptidos objetivo. | |
| BR112023003468A2 (pt) | Variantes de uma xiloglucanase da família 44 | |
| NO20062948L (no) | Promotere for ekspresjon i modifisert vaccinia-virus Ankara | |
| BR112023025616A2 (pt) | Codificação de ácido nucleico para proteína de fusão klk2-gpi, células recombinantes e usos das mesmas | |
| BR112022026248A2 (pt) | Conjugados de citocinas | |
| PY23103696A (es) | Polipéptidos de la familia de carbohidrato esterasas 3 (ce3) que tienen actividad de acetil xilano esterasa y polinucleótidos que los codifican | |
| BR112019003950A2 (pt) | identificação de mutações em variantes de canalopsina que têm sensibilidade à luz melhorada e métodos de uso da mesma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11N | Dismissal: publication cancelled [chapter 11.14 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 11.1 NA RPI NO 2841 DE 17/06/2025 POR TER SIDO INDEVIDA. |